Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Gross Margin (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Gross Margin data on record, last reported at 51.42% in Q3 2025.

  • For Q3 2025, Gross Margin fell 189.0% year-over-year to 51.42%; the TTM value through Dec 2025 reached 191.89%, up 14081.0%, while the annual FY2024 figure was 51.08%, 341.0% down from the prior year.
  • Gross Margin reached 51.42% in Q3 2025 per AMPH's latest filing, up from 1356.2% in the prior quarter.
  • Across five years, Gross Margin topped out at 60.04% in Q3 2023 and bottomed at 1356.2% in Q1 2025.
  • Average Gross Margin over 5 years is 27.9%, with a median of 50.62% recorded in 2023.
  • Peak YoY movement for Gross Margin: skyrocketed 1133bps in 2023, then plummeted -140864bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 46.52% in 2021, then rose by 13bps to 52.71% in 2022, then grew by 2bps to 53.98% in 2023, then fell by -14bps to 46.45% in 2024, then rose by 11bps to 51.42% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 51.42% in Q3 2025, 1356.2% in Q1 2025, and 46.45% in Q4 2024.